Jason A.  Leverone net worth and biography

Jason Leverone Biography and Net Worth

Jason Leverone is the Chief Financial Officer. He brings over 25 years of strategic finance and operational experience across multiple industries, including over 19 years in life sciences. Prior to joining OnKure, Mr. Leverone served as the Chief Financial Officer and Secretary of miRagen Therapeutics, Inc, a publicly traded biotechnology company which merged with Viridian Therapeutics, Inc. in 2020. During his tenure at miRagen, he held roles of increasing responsibility in operations, corporate finance and strategic planning, including key roles in the Company’s public offering, strategic license transactions, and mergers and acquisitions. Prior to joining miRagen, Mr. Leverone served as Senior Director of Finance and Controller for Replidyne, Inc., a publicly traded biotechnology company acquired in 2009. He also served as Corporate Controller for CreekPath Systems, Inc., a private international software development company. Mr. Leverone began his professional career in public accounting at Ernst and Young LLP and continued with Arthur Andersen LLP. He is a Certified Public Accountant and earned a B.S. in Business Administration from Bryant University.

What is Jason A. Leverone's net worth?

The estimated net worth of Jason A. Leverone is at least $77.46 thousand as of June 22nd, 2026. Mr. Leverone owns 18,802 shares of OnKure Therapeutics stock worth more than $77,464 as of July 27th. This net worth estimate does not reflect any other investments that Mr. Leverone may own. Learn More about Jason A. Leverone's net worth.

How do I contact Jason A. Leverone?

The corporate mailing address for Mr. Leverone and other OnKure Therapeutics executives is 18575 Jamboree Road Suite 275-S, Irvine CA, 92612. OnKure Therapeutics can also be reached via phone at 858-283-0280 and via email at [email protected]. Learn More on Jason A. Leverone's contact information.

Has Jason A. Leverone been buying or selling shares of OnKure Therapeutics?

Jason A. Leverone has not been actively trading shares of OnKure Therapeutics over the course of the past ninety days. Most recently, Jason A. Leverone sold 303 shares of the business's stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $4.40, for a transaction totalling $1,333.20. Following the completion of the sale, the chief financial officer now directly owns 18,802 shares of the company's stock, valued at $82,728.80. Learn More on Jason A. Leverone's trading history.

Are insiders buying or selling shares of OnKure Therapeutics?

During the last twelve months, insiders at the sold shares 8 times. They sold a total of 1,556 shares worth more than $5,501.27. The most recent insider tranaction occured on June, 22nd when CEO Nicholas A Saccomano sold 86 shares worth more than $378.40. Insiders at OnKure Therapeutics own 2.2% of the company. Learn More about insider trades at OnKure Therapeutics.

Information on this page was last updated on 6/22/2026.

Jason A. Leverone Insider Trading History at OnKure Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/22/2026Sell303$4.40$1,333.2018,802View SEC Filing Icon  
3/23/2026Sell301$4.16$1,252.1616,000View SEC Filing Icon  
12/22/2025Sell302$2.97$896.9416,301View SEC Filing Icon  
9/22/2025Sell303$2.62$793.8612,603View SEC Filing Icon  
6/23/2025Sell303$2.38$721.1412,906View SEC Filing Icon  
4/7/2025Sell1,844$2.67$4,923.4813,209View SEC Filing Icon  
4/4/2025Sell1,278$3.33$4,255.7415,053View SEC Filing Icon  
See Full Table

Jason A. Leverone Buying and Selling Activity at OnKure Therapeutics

This chart shows Jason A Leverone's buying and selling at OnKure Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

OnKure Therapeutics Company Overview

OnKure Therapeutics logo
OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.
Read More

Today's Range

Now: $4.27
Low: $4.19
High: $4.38

50 Day Range

MA: $4.23
Low: $3.08
High: $4.60

2 Week Range

Now: $4.27
Low: $1.91
High: $5.38

Volume

5,238 shs

Average Volume

268,312 shs

Market Capitalization

$172.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27